Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 1
2007 2
2008 1
2009 3
2010 1
2012 2
2013 1
2014 1
2015 1
2019 3
2021 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. Among authors: zolnierek j. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J. Motzer RJ, et al. Among authors: zolnierek j. Lancet Oncol. 2015 Nov;16(15):1473-1482. doi: 10.1016/S1470-2045(15)00290-9. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26482279 Clinical Trial.
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y. Matsubara N, et al. Among authors: zolnierek j. Eur Urol. 2024 Mar;85(3):229-238. doi: 10.1016/j.eururo.2023.08.012. Epub 2023 Sep 29. Eur Urol. 2024. PMID: 37778952 Free article. Clinical Trial.
Antisense therapy in cancer.
Pawlak W, Zolnierek J, Sarosiek T, Szczylik C. Pawlak W, et al. Among authors: zolnierek j. Cancer Treat Rev. 2000 Oct;26(5):333-50. doi: 10.1053/ctrv.2000.0173. Cancer Treat Rev. 2000. PMID: 11006135 Review.
Targeted therapy of renal cell cancer.
Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Wysocki PJ, et al. Among authors: zolnierek j. Curr Opin Investig Drugs. 2008 Jun;9(6):570-5. Curr Opin Investig Drugs. 2008. PMID: 18516756 Review.
Recent developments in renal cell cancer immunotherapy.
Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Wysocki PJ, et al. Among authors: zolnierek j. Expert Opin Biol Ther. 2007 May;7(5):727-37. doi: 10.1517/14712598.7.5.727. Expert Opin Biol Ther. 2007. PMID: 17477809 Review.
21 results